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Background:  Lipoprotein (a) [Lp(a)] is a preferential lipoprotein carrier of oxidized phospholipids (OxPL). OxPL on apoB-100 particles (OxPL/
apoB) independently predicts cardiovascular disease (CVD) events. Since apo(a) exhibits high sequence homology to plasminogen, we hypothesized 
that plasminogen may also contain OxPL.
Methods:  Plasminogen from commercially available preparations and plasma from chimpanzees, gorillas, bonobos, cynomolgus monkeys, wild-
type, apoE-/-, LDLR-/-, and Lp(a)-transgenic mice, healthy humans and patients with familial hypercholesterolemia, stable cardiovascular disease 
and acute coronary syndromes (ACS) were subjected to various biochemical analytical techniques. OxPL present on plasminogen were detected with 
monoclonal antibody E06 using a variety of sandwich chemiluminescent ELISAs and immunoblot analyses.
Results:  Immunoblot, immunoprecipitation, density gradient ultracentrifugation and ELISA analyses demonstrated that all human and animal 
plasma samples tested had significant amounts of OxPL on plasminogen. EO6-detectable OxPL were present on plasminogen in non-lipoprotein 
fractions but on Lp(a) in lipoprotein fractions. Using ELISA techniques, OxPL/apoB and OxPL/apo(a) in human plasma varied significantly (~50X) 
among subjects and correlated with Lp(a), whereas OxPL/plasminogen levels were fairly constant across a relatively narrow range (<2X) and did not 
correlate with Lp(a). In serial measurements, OxPL/plasminogen levels did not vary in normal subjects or patients with stable CVD, but increased 
acutely over the first month and then slowly decreased over a 7-month follow-up period in patients following ACS.
Conclusion: These data demonstrate that plasminogen of all species studied contain OxPL. OxPL on plasminogen vary in a narrow range and 
represent a second major source of OxPL in plasma in addition to Lp(a). OxPL on plasminogen may have pathophysiological implications in 
atherothrombosis.
